Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance

Stock Track11-06

ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp decline suggests investors may be focusing on other factors beyond the headline numbers.

The company reported Q3 revenue of $134.2 million, surpassing analyst estimates of $130.5 million and representing a 12% year-over-year increase. Earnings per share came in at $0.15, meeting consensus expectations. ADMA also posted strong profitability metrics, with adjusted EBITDA of $58.7 million and adjusted net income of $38.9 million for the quarter.

In a positive development, ADMA raised its full-year 2025 revenue guidance to at least $510 million, up from its previous forecast of more than $500 million. The company also reported record demand for its ASCENIV product and anticipates expanded payer coverage in 2026, which could support sustained growth. Despite these encouraging factors, the after-hours stock plunge suggests investors may be concerned about other aspects of the report, such as potential challenges in the standard IVIG market or the impact of a higher effective tax rate on future earnings.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126909388?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126909388","market":"sg","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp decline suggests investors may be focusing on other factors beyond the headline numbers.</p>\n\n<p>The company reported Q3 revenue of $134.2 million, surpassing analyst estimates of $130.5 million and representing a 12% year-over-year increase. Earnings per share came in at $0.15, meeting consensus expectations. ADMA also posted strong profitability metrics, with adjusted EBITDA of $58.7 million and adjusted net income of $38.9 million for the quarter.</p>\n\n<p>In a positive development, ADMA raised its full-year 2025 revenue guidance to at least $510 million, up from its previous forecast of more than $500 million. The company also reported record demand for its ASCENIV product and anticipates expanded payer coverage in 2026, which could support sustained growth. Despite these encouraging factors, the after-hours stock plunge suggests investors may be concerned about other aspects of the report, such as potential challenges in the standard IVIG market or the impact of a higher effective tax rate on future earnings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp decline suggests investors may be focusing on other factors beyond the headline numbers.</p>\n\n<p>The company reported Q3 revenue of $134.2 million, surpassing analyst estimates of $130.5 million and representing a 12% year-over-year increase. Earnings per share came in at $0.15, meeting consensus expectations. ADMA also posted strong profitability metrics, with adjusted EBITDA of $58.7 million and adjusted net income of $38.9 million for the quarter.</p>\n\n<p>In a positive development, ADMA raised its full-year 2025 revenue guidance to at least $510 million, up from its previous forecast of more than $500 million. The company also reported record demand for its ASCENIV product and anticipates expanded payer coverage in 2026, which could support sustained growth. Despite these encouraging factors, the after-hours stock plunge suggests investors may be concerned about other aspects of the report, such as potential challenges in the standard IVIG market or the impact of a higher effective tax rate on future earnings.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1126909388","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126909388","pubTimestamp":1762379705,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"个股追踪|ADMA Biologics盘后暴跌5.72%，尽管Q3业绩强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics (NASDAQ:ADMA) shares tumbled 5.72% in after-hours trading on Wednesday, despite reporting better-than-expected third-quarter results and raising its full-year guidance. The sharp decline suggests investors may be focusing on other factors beyond the headline numbers.\nThe company reported Q3 revenue of $134.2 million, surpassing analyst estimates of $130.5 million and representing a 12% year-over-year increase. Earnings per share came in at $0.15, meeting consensus expectations. ADMA also posted strong profitability metrics, with adjusted EBITDA of $58.7 million and adjusted net income of $38.9 million for the quarter.\nIn a positive development, ADMA raised its full-year 2025 revenue guidance to at least $510 million, up from its previous forecast of more than $500 million. The company also reported record demand for its ASCENIV product and anticipates expanded payer coverage in 2026, which could support sustained growth. Despite these encouraging factors, the after-hours stock plunge suggests investors may be concerned about other aspects of the report, such as potential challenges in the standard IVIG market or the impact of a higher effective tax rate on future earnings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126909388","isCrawlerRequest":true}